These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 30397837)

  • 21. Multi-Organ Protective Effects of Sodium Glucose Cotransporter 2 Inhibitors.
    Yanai H; Hakoshima M; Adachi H; Katsuyama H
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922546
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of canagliflozin on myocardial infarction: a post hoc analysis of the CANVAS programme and CREDENCE trial.
    Yu J; Li J; Leaver PJ; Arnott C; Huffman MD; Udell JA; Perkovic V; Mahaffey KW; de Zeeuw D; Fulcher G; Matthews DR; Shaw W; Rosenthal N; Neal B; Figtree GA
    Cardiovasc Res; 2022 Mar; 118(4):1103-1114. PubMed ID: 33826709
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cardiovascular effects of sodium glucose cotransporter 2 inhibitors.
    Cavaiola TS; Pettus J
    Diabetes Metab Syndr Obes; 2018; 11():133-148. PubMed ID: 29695924
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Canaglifozin results in cardiovascular and renal protection in patients with type 2 diabetes : from CANVAS to CREDENCE].
    Scheen AJ
    Rev Med Liege; 2019 Oct; 74(10):508-513. PubMed ID: 31609553
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SGLT2 inhibitors with cardiovascular benefits: Transforming clinical care in Type 2 diabetes mellitus.
    d'Emden M; Amerena J; Deed G; Pollock C; Cooper ME
    Diabetes Res Clin Pract; 2018 Feb; 136():23-31. PubMed ID: 29196150
    [TBL] [Abstract][Full Text] [Related]  

  • 26. How representative of a general type 2 diabetes population are patients included in cardiovascular outcome trials with SGLT2 inhibitors? A large European observational study.
    Birkeland KI; Bodegard J; Norhammar A; Kuiper JG; Georgiado E; Beekman-Hendriks WL; Thuresson M; Pignot M; Herings RMC; Kooy A
    Diabetes Obes Metab; 2019 Apr; 21(4):968-974. PubMed ID: 30537226
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Advances in reducing cardiovascular risk in the management of patients with type 2 diabetes mellitus.
    Hu Y
    Chronic Dis Transl Med; 2019 Mar; 5(1):25-36. PubMed ID: 30993261
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pleiotropic effects of SGLT2 inhibitors beyond the effect on glycemic control.
    Satoh H
    Diabetol Int; 2018 Oct; 9(4):212-214. PubMed ID: 30603370
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials.
    Lytvyn Y; Bjornstad P; Udell JA; Lovshin JA; Cherney DZI
    Circulation; 2017 Oct; 136(17):1643-1658. PubMed ID: 29061576
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SGLT2 Inhibitors and Cardiovascular Outcomes: Current Perspectives and Future Potentials.
    Jia X; Mehta PB; Ye Y; Alam M; Birnbaum Y; Bajaj M
    Curr Diab Rep; 2018 Jul; 18(9):63. PubMed ID: 29995242
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical potential relevance of metabolic properties of SGLT2 inhibitors in patients with heart failure.
    Galli M; D'Amario D; Sofia C; Vaccarella M; Crea F; Aspromonte N
    Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1273-1285. PubMed ID: 30472914
    [No Abstract]   [Full Text] [Related]  

  • 32. Cardiovascular protection in type 2 diabetes: Insights from recent outcome trials.
    Bailey CJ; Marx N
    Diabetes Obes Metab; 2019 Jan; 21(1):3-14. PubMed ID: 30091169
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
    Heerspink HJ; Perkins BA; Fitchett DH; Husain M; Cherney DZ
    Circulation; 2016 Sep; 134(10):752-72. PubMed ID: 27470878
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exploring the heterogeneity of the effects of SGLT-2 inhibitors in cardiovascular outcome trials.
    Mannucci E; Dicembrini I; Nreu B; Monami M
    Nutr Metab Cardiovasc Dis; 2020 Jan; 30(1):71-76. PubMed ID: 31757568
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardiovascular outcomes of sodium-glucose cotransporter 2 inhibitors: A comprehensive review of clinical and preclinical studies.
    Ghosh RK; Bandyopadhyay D; Hajra A; Biswas M; Gupta A
    Int J Cardiol; 2016 Jun; 212():29-36. PubMed ID: 27017118
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.
    Wanner C; Lachin JM; Inzucchi SE; Fitchett D; Mattheus M; George J; Woerle HJ; Broedl UC; von Eynatten M; Zinman B;
    Circulation; 2018 Jan; 137(2):119-129. PubMed ID: 28904068
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SGLT2 inhibition and heart failure-current concepts.
    Custodio JS; Duraes AR; Abreu M; Albuquerque Rocha N; Roever L
    Heart Fail Rev; 2018 May; 23(3):409-418. PubMed ID: 29704192
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i): Their Role in Cardiometabolic Risk Management.
    Katsiki N; Mikhailidis DP; Theodorakis MJ
    Curr Pharm Des; 2017; 23(10):1522-1532. PubMed ID: 28088910
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Do the SGLT-2 Inhibitors Offer More than Hypoglycemic Activity?
    Flores E; Santos-Gallego CG; Diaz-Mejía N; Badimon JJ
    Cardiovasc Drugs Ther; 2018 Apr; 32(2):213-222. PubMed ID: 29679303
    [TBL] [Abstract][Full Text] [Related]  

  • 40. How Generalizable Are Cardiovascular Outcome Trials of Sodium-Glucose Co-Transporter-2 Inhibitors? A National Database Study: Study Protocol.
    Hinton W; Feher MD; Munro N; de Lusignan S
    Diabetes Ther; 2019 Jun; 10(3):1163-1170. PubMed ID: 31041781
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.